Annamaria Gullà

Annamaria Gullà, MD, is an oncologist and Group Leader at the Candiolo Cancer Institute FPO - I.R.C.C.S. in Italy. She is a physician-scientist with a strong expertise in experimental hemato-oncology with primary focus on multiple myeloma. She earned her MD degree and completed her clinical/research fellowship in Medical Oncology at the Magna Graecia University of Catanzaro (Italy). She then completed a postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School in Boston (U.S.) where she was promoted as junior faculty and Instructor in Medicine at Harvard Medical School. Dr. Gullà research focuses on the mechanisms of anticancer immune-surveillance and on the role of immunogenic chemotherapy in multiple myeloma.  She has a record of accomplished and productive research projects, resulting in several publications in international peer-reviewed journals. Her works have been highlighted at several international meetings including the annual meetings of the American Society of Hematology (ASH) and the International Myeloma Society. Her projects were also funded by competitive career development awards including the ASH Fellow to Faculty Scholar Award (2020-2022) and Leukemia and Lymphoma Society Career Development Program Award (2019-2022).